

The Neurology Center of Southern California  
6010 Hidden Valley Road, Suite 200, Carlsbad, California 92011  
9850 Genesee Ave, Suite 470, La Jolla, CA, 92037  
1955 Citracado Pkwy, Suite 102, Escondido, CA 92029  
15611 Pomerado Road, Suite 505 Poway, CA 92064

Phone: 760-631-3000  
Fax: 760-631-3016



## *Anchi Wang, M.D.*

---

---

### EDUCATION

---

---

Escuela Autonoma De Ciencias Medicas de Centro America  
Universidad Autonoma de Centro America  
**San Jose, Costa Rica ■ July 1985 – June 1991**  
M.D.

Volunteer Work and Traveled 1991 – 1997

University of Texas Southwestern Medical Center  
**Dallas, Texas ■ July 1997 – June 1998**  
Internship, **Internal Medicine**

University of Texas Southwestern Medical Center  
**Dallas, Texas ■ July 1998 – June 2001**  
Residency, **Neurology**

Baylor College of Medicine  
**Houston, Texas ■ July 2001 – June 2002**  
Fellowship, **Movement Disorders**

---

---

### LICENSURE

---

---

California Medical License Number – A79381

---

---

### CERTIFICATIONS

---

---

American Board of Psychiatry and Neurology ■ June 2009

---

---

### RELATED EXPERIENCE

---

---

**Neurologist, Private Group Practice**, North County Neurology Associates dba The Neurology Center, Carlsbad, CA ■ January 2016 – Present

**Neurologist, Private Group Practice**, North County Neurology Associates dba The Neurology Center, Oceanside, CA ■ August 2002 – January 2016

---

---

### RELATED EXPERIENCE CON'T

---

---

**Neurologist**, The Research Center of Southern California, LLC, Carlsbad, CA ■ January, 2016 – Present

**Neurologist**, The Research Center of Southern California, LLC, Encinitas & Oceanside, CA ■ 2007 – January 2016

---

---

### HOSPITAL AFFILIATIONS

---

---

Tri-City Medical Center, Oceanside, Ca, Active ■ 2002 – Present

Scripps Memorial Hospital, Encinitas, Ca, Active ■ 2003 – Present

Scripps Memorial Hospital, La Jolla, Ca, Courtesy, ■ 2003 – Present

---

---

### PUBLICATIONS AND PAPERS

---

---

Wagner, G., Rosen, J., Holguin, G., Frishberg, B., **Wang, A.**, Sahagian, G., Haase-Alasantro, L. (2016). Clinical Assessment of Posterior Cortical Atrophy. Poster presented at the National Academy of Neuropsychology Conference, Seattle, WA.

**Wang, A.**, and Jankovic, J., *Hemifacial spasm: clinical findings and treatment*, Muscle and Nerve 21:1740-1747, 1998

**Wang, A.**, Fathallah-Shaykh, H. and Rosenberg, R.N. Case 24 “*Acute Vertigo and Ataxia*”, pp.201-207. clinical Cases in Neurology; Edited by A.H.V. Schapira and L.P. Rowland; Butterworth-Heinemann Inc., Oxford and Buxton; 2001.

William G. Ondo, **Anchi Wang**, Madhavi Thomas and Kevin Dat Vuong, “Evaluating factors that can influence spirography ratings in patients with essential tremor”, *Parkinsonism & Related Disorders*, Volume 11, Issue 1, January 2005, Pages 45-48,

---

---

### RESEARCH ACTIVITIES

---

---

#### **Alzheimer’s Disease**

TVP1012-A001-201- A 1-Year, double-blind, randomized, placebo-controlled study of Rasagiline 1 mg and 2 mg added to Aricept 10 mg daily in patients with mild to moderate dementia of the Alzheimer’s type.” Sub-Investigator, 2005.

VP-AD-301 “A Double-Blind Placebo-Controlled Study of VP4896 for the Treatment of Mild to Moderate Alzheimer’s Disease.” Sub-Investigator, 2006.

PRX-03140 “A Randomized, Double-Blind, Placebo Controlled, Phase IIa Study to Assess the Short-Term Effects of PRX-03140 Alone and in Combination with Donepezil in Subjects with Mild Alzheimer’s Disease.” Sub-Investigator, 2006

---

---

**RESEARCH ACTIVITIES CONT’D**

15/Mar/2016

---

---

**Alzheimer’s Studies Cont’d**

ELN115727-301 & 302 “A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AA-001, ELN115727 in Patients with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein E $\epsilon$ 4 Non-Carriers (301) or Non-Carriers (302).” Sub-Investigator, 2008

ELN115727-351 “A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Alzheimer’s Disease who Participated in Study ELN115727-301 or in Study ELN115727-302.” – 2009

AAB-001-SC-ALZ-2003 “ A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects with Mild to Moderate Alzheimer’s Disease.” – 2010

Protocol #14862A “Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with Donepezil; Study 2; 4/2015 - current

**Epilepsy**

E2080-A001-301 “A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures.” Sub Investigator, 2006

**Migraine**

MT300-401 “A Multicenter Randomized, Single-Blind, Evaluation of Three Injectable Anti-Migraine Drugs.” - Sub-Investigator – 2003

CL1776-005 – “A Phase 2 Safety and Efficacy Study of NPS 1776 for the Acute Treatment of Migraine Headaches.” – Sub Investigator – 2004

001 – “A Randomized, Evaluator-Masked Trial to Evaluate the Efficacy of Botox Compared with Depakote in Migraine Prevention.” – Sub-Investigator – 2004

3420AG1 – “Program to Assess Treatment Strategies: A Botox Observational Program.” – Sub Investigator – 2003

MT400-303 “An Open-label, Repeat Dose Study of the Safety of Combo Formulation in the Treatment of Multiple Episodes of Acute Migraine Over 12 Months.” Sub – Investigator, 2004

065-00- (Maxalt) "A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10-mg Tablet Administered Early During a Migraine Attack While the Pain is Mild." Sub-Investigator, 2004

MT400-301 (POZEN) "A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study To Evaluate The Safety And Efficacy Of Trexima In The Acute Treatment Of Migraine Headaches." Sub-Investigator, 2004

15/Mar/2016

---

---

## RESEARCH ACTIVITIES CONT'D

---

---

### Migraine Studies Cont'd

VML251-3MRM/02 "A double-blind, placebo-controlled, parallel group study, with an open-label extension phase, to assess the efficacy, tolerability and safety of oral frovatriptan in the prevention of menstrually related migraine (MRM) headaches in a "difficult to treat" population." Sub-Investigator, 2005.

E2007-A001-210- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 in Migraine Prophylaxis. Sub-Investigator, 2005.

"A Single-Center, Double-Blind Comparison of Botox and Topiramate for the Prophylactic Treatment of Chronic Migraine Headache". Sub-Investigator 2005

A Single-Center, Double-Blind Comparison of BOTOX® (Botulinum Toxin Type A) and DEPAKOTE® for the Prophylactic Treatment of Migraine Headaches- Pilot Study." Sub-Investigator

191622-080 "A Multicenter Study Evaluating the Efficacy and Safety of Botox Purified Neurotoxin complex as Headache Prophylaxis In Migraine Patients with 15 or More headache Days per 4-Week Period in a 24 week, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Phase Followed by a 32 Week Open-Label Phase." Sub-Investigator 2006

TRX103632/635 "A Randomized, Double-Blind, Multi-Center, Placebo Controlled, Cross-Over Study to Determine the Consistency of Response for TREXIMA (Sumatriptan 85mg/Naproxen Sodium 500mg) in the Acute Treatment of Multiple Migraine Attacks." Sub-Investigator 2006

TRX106573 "A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Cross-Over Study of Trexima® in Migraine Subjects Who Report Poor Response or Intolerance to Relpax® ." Sub-Investigator, 2006

NL-2006-001 "A Phase III Randomized, Double-Blind, Parallel Group, Sham-Controlled Study Evaluating the Efficacy and Safety of Non-Invasive, Non-Repetitive Transcranial TMS Stimulation (TMS) for the Acute Preemptive Treatment of the Aura Phase of Migraine Headache." Sub-Investigator, 2007

TON/03/07-CLIN "A Multi-Centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache and Open Label Extension." Sub-Investigator 2007

BTX0805 "Safety and Efficacy of Botulinum Neurotoxin Type A in the Treatment of Forward Head Posture with Associated Chronic Tension Type Headache using a Novel Fixed site Injection Paradigm." Sub-Investigator, 2009

0462-082-00 “ A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents.” Sub-Investigator, 2010

---

---

**RESEARCH ACTIVITIES CONT'D**

---

---

15/Mar/2016

**Migraine Studies Cont'd**

COMPEL An open-label, multicenter study of the long-term efficacy, safety and tolerability of BOTOX for the prophylaxis of headaches in adult patients with chronic migraine.” Sub-Investigator, 2012

**Multiple Sclerosis**

CAMMS223 – “A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low and High Dose CAMPATH (MABCAMPATH) and High Dose Rebif in Patient with Early, Active Relapsing-Remitting Multiple Sclerosis.” – Sub Investigator – 2003

9006- (TEVA) “A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of 40mg of Copaxone in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients.” Sub-Investigator, 2004

A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis with optional extension phase Protocol No.: CFTY720D2309

Extension to CFTY720D2309 (A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5mg and 1.25mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis.” 2006

28821 “A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Oral Cladribine in Subjects with a First Clinical Event at High Risk of Converting to MS.” – 2006

CFTY720D2302: A 12-month double-blind, randomized, multicenter, active-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus interferon  $\beta$ -1a (Avonex®) administered i.m. once weekly in patients with relapsing-remitting multiple sclerosis with optional Extension Phase.” - 2007

MPB8298-SP-03 “A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis.” 2007

ACT 10573 “A Double Blind, Placebo-Controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispiridine on Visual Function in Patients with Multiple Sclerosis.” – 2008.

DRI10566: “A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispiridine 50 mg, 100 mg, and 200 mg in Patients with Multiple Sclerosis.” 2009

29652 “ A 12-week, Phase IIIb, Open-Label, Single-Arm, Multicenter Trial to Evaluate Ease of use of an Electronic Autoinjector (RebiSmart™) for Self-Injection in Subjects with Relapsing Multiple Sclerosis (RMS) treated with Rebif® 44mcg Subcutaneously three times a week.” - 2009

---

---

**RESEARCH ACTIVITIES CON'T**

---

---

15/Mar/2016

**Multiple Sclerosis *Continued***

Nerispidine (HP184) - Clinical Trial - ACT10573: A double-blind, placebo-controlled, randomized crossover, activity study of oral doses of 50 mg and 400 mg nerispidine on visual function in patients with multiple sclerosis, IND # 61,494.” – 2009

H9B-MC-BCDJ (a) –Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis.” - 2009

101MS325 “A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon  $\beta$  1a) to Natalizumab in Subjects with Relapsing Remitting Multiple Sclerosis.” – 2010

A 6-month, Randomized, Active Comparator, Open-label, Multi- Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod 0.5 mg/day in Patients with Relapsing Forms of Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy (EPOC).” – 2010

EFC6058 “A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta.” – 2010

RebiDose Human Factors. A three-arm multicenter trial to preform human factors testing of the investigational RebiDose ready to use single use auto injector device including simulated injections in subjects with relapsing multiple sclerosis (RMS), caregivers, and nurses.” Sub-investigator, 2011

RebiSmart Human Factors, A three-arm, multicenter trial to perform human factors testing of the investigational RebiSmart electronic auto-injector device including simulated injections in subjects with relapsing multiple sclerosis (RMS), caregivers, and nurses.” Sub-Investigator, 2012

**Pain**

A1A20004 “A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Tolerability of a 14 Day Treatment Course of GW493838 50mg Compared to Placebo in Subjects with Peripheral Neuropathic Pain.” Sub-Investigator – November 2002 – 2003

**Parkinson's Disease**

666E-CNS-0075-021 “A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanriole Versus Placebo or Ropinirole in Patients with Early Parkinson's Disease.” Sub-Investigator – 2002 – 2003

M/2760/0011 “PNU-95666E: Open-Label, Long Term, Flexible Dose Study of Safety, Tolerability and Therapeutic Response in Patients with Parkinson’s Disease.” Sub-Investigator – 2003

DA2APD-0075-031 “A Phase III, Double-blind, Fixed Dose Response Study Comparing the Efficacy and Safety of Sumanitrole vs. Placebo in Patients with Early Parkinson’s Disease.” Sub-Investigator, 2003

---

---

**RESEARCH ACTIVITIES CONT’**

---

---

15/Mar/2016

**Parkinson’s Studies Cont’d**

1198.100 NS2330 “A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson’s Disease Patients (Study for Proof of Concept in Early Parkinson’s Disease of a Triple Reuptake Inhibitor, NS2330 / SCEPTRE).” Sub-Investigator – April 2004

S308-3-003 “ A Multi-Centre, Randomized, Double-Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease.” Sub-Investigator, 2006

S308-3-008 “An extension of SLV308, A multicenter, randomized, double-blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of monotherapy in the treatment of patients with early stage Parkinson’s disease.” 2007

Droxidopa NOH306 “A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Parkinson’s Disease.” – 2010

S187.3.002 “A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson’s Subjects Receiving Optimized Treatments with Parkinson Medicinal Products, who Continue to Experience Persistent Motor Fluctuations.” – 2010

S187.3.003 “Open-Label, 12-Month Safety and Efficacy Study of Levodopa – Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson’s Disease Subjects.” – 2010.

S187.3.004 “An Open-Label, 12 Month Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson’s Disease and Severe Motor-Fluctuations Despite Optimized Treatment with Available Parkinson’s Disease Medications” – 2010

S187.3.005 “Open-Label Continuation Treatment Study with Levodopa – Carbidopa Intestinal Gel In Subjects With Advanced Parkinson’s Disease And Severe Motor-Fluctuation Who Have Exhibited A Persistent And Positive Effect To Treatment in Previous Studies.” – 2010.

**Stroke**

YM872 “A Randomized, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study to evaluate the Safety of YM872 in Patients with Acute Ischemic Stroke.” Sub-Investigator- 1998-2003.

EFC4505 “Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA).” Sub-Investigator

Botox vs. Zanaflex “Placebo Controlled Trial of BOTOX ® versus Zanaflex ® for the Treatment of Subjects with Post- Stroke Upper Limb Spasticity.” Sub-Investigator – March 2003

---

---

RESEARCH ACTIVITIES CONT'D

---

**Stroke continued**

15/Mar/2016

100282 Bayer Study “A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients with Acute Ischemic Stroke.” Sub-Investigator, 2003

9.159 “PRoFESS – Prevention Regimen for Effectively avoiding Second Strokes: A double-blind, active and placebo controlled study of Aggrenox vs. clopidogrel, with and without Micardis” Sub Investigator.” 2004 – Present

SA-NXY-0007: “A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke.” Sub Investigator, 2004

SA-NXY-0012- (CHANT) “A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb Study to Assess The Safety And Tolerability Of 72 Hours Intravenous Infusion of NXY-059 In Adult Patients with Intracerebral Hemorrhage (ICH).” Sub-Investigator, 2004

Ptcl-01213 entitled: “A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel study to evaluate the effects of DP-b99 on Neurologic Function and Disability in subjects with Acute Ischemic Hemispheric Stroke.” Sub-Investigator, 2004

F7ICH-1641 A Randomized, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niasase® in Acute Intracerebral Hemorrhage.” Sub-Investigator, 2005

NTI-ASP-0502 “A Randomized, Double-Blind, Placebo Controlled Study of Ancrod (Viprinex) in Subjects Beginning Treatment within 6 Hours of the Onset of Acute Ischemic Stroke.” Sub-Investigator, 2006

CD-0125 “Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke.” Sub Investigator, 2006

NTS-INT06-007 “A Double-Blind, Randomized, Controlled, Parallel Group, Multi-Centre, Pivotal Study to Assess the Safety and Effectiveness of the Treatment of Acute Ischemic Stroke with the NeuroThera® Laser System within 24 Hours from Stroke Onset”. Principal Investigator, 2007

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50) P04737-3694.” Sub-Investigator, 2007

P04737 “A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a history of



Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events". Sub-Investigator, 2008

NTS-INT08-009 " A double-blind, randomized, sham-controlled, parallel group, multicenter, pivotal study to assess the safety and efficacy of transcranial laser therapy with the NeuroThera® Laser System for the treatment of acute ischemic stroke within 24 hours of stroke onset." – 2010.

---

---

RESEARCH ACTIVITIES CONT

15/Mar/2016

**Stroke Continued**

01373 "A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset." Sub-Investigator, 2010.

**Other**

GAL-COG-3002- "An Analysis of Mortality in Subjects who participated in Three Studies of Galantamine in Mild Cognitive Impairment", Sub-Investigator, 2004

101468/205: A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients with Restless Legs Syndrome." Sub-Investigator, 2005

E2020-A001-412: A One Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride (E2020) in Subjects with Mild Cognitive Impairment." Sub-Investigator, 2005

"A Randomized, Double-blind, Placebo Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Botulinum Neurotoxin Type A in the Treatment of Forward Head Posture with Associated Chronic Tension Type Headache using a Novel Fixed site Injection Paradigm." Sub-Investigator 2009

Sub-Investigator - TBI-01: A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients with Chronic Motor Deficit from Traumatic Brain Injury (TBI) 2015 - Present